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Biology of TGF- in knockout and transgenic mouse models. This
paper reviews the basic biology and biochemistry of the TGF- isoforms
including their unique serine-threonine receptors and signaling interme-
diates. Dysregulation of TGF-f3 expression and/or receptor/signaling
function have been implicated in a wide variety of pathologies. We will
discuss mechanisms underlying some of these disease processes as gained
from study of transgenic mice in which expression of TGF-131 has either
been lost by targeted deletion of its gene, is overexpressed in a tissue-
specific manner, or blocked by its latency associated peptide.
Physiology and pathophysiology of TGF-j3 and its receptors
Transforming growth factor-a (TGF-) is a multifunctional
cytokine with effects on nearly every tissue and cell type [1, 2].
Three distinct isoforms of the peptide are found in mammalian
species and expressed in unique patterns, although each isoform
appears to signal through the same set of cell surface receptors
[3—51. This suggests that isoform-specific effects lie upstream of
the signaling receptors and likely involve differential activation of
the promoters as well as possible differences in extracellular
localization, trafficking, and activation from their respective latent
forms. Principal effects of TGF-f3 on cells include inhibition of the
growth of hematopoietic, epithelial, and endothelial cells, stimu-
lation of chemotaxis of cells including lymphocytes, macrophages,
and fibroblasts, and stimulation of matrix protein production by
mesenchymal cells [6]. The most concentrated source of TGF-J3 is
that of the type I isoform in platelet alpha granules consistent
with its critical roles in repair of soft tissue and in fracture healing
[7]. Dysregulated expression of or response to TGF-p has been
implicated in a wide variety of disease processes including auto-
immune disease [8, 1, fibrotic disease and chronic inflammation
[10, 11], parasitic disease [12], neurodegenerative disease [13],
and carcinogenesis [14, 15]; in almost every case this dysregulation
involves the type 1 isoform of TGF-/3 consistent with predictions
based on analysis of its promoter [16].
TGF-/3s signal through serine-threonine kinase receptors
In contrast to many mitogenic growth factors that signal
through receptors having intrinsic tyrosine kinase activity or that
collaborate intracellularly with tyrosine kinases, most members of
the TGF-f3 superfamily of ligands signal through a multimeric
receptor complex consisting of type I and type II receptors, each
of which has intrinsic serine-threonine kinase activity [3—51. Signal
transduction is initiated by a sequence of events involving: (1)
binding of the ligand to the type II receptor; (2) recruitment of the
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type I receptor to the liganded type II receptor complex; (3)
transphosphorylation of a glycine-serine-rich domain (GS do-
main) of the type I receptor by the type II receptor; and (4)
propagation of the signal (Fig. 1) [17]. The signal transduction
pathways have yet to be elucidated in any detail. However, in
recent months there has been an explosion of research focused on
a family of at least six mammalian proteins related to Drosophila
Mad (Mothers against dpp), a cytoplasmic protein shown by
genetic analysis to lie downstream of a TGF-3-family ligand called
decapentaplegic (dpp) [18, 191. Proteins belonging to this family
have no known structural or functional motifs, but have been
shown to mediate developmental signals from TGF-j3 superfamily
ligands in not only Drosophila, hut also in C. elegans and Xenopus
[20, 21]. A pattern is now emerging from studies in both Xenopus
and mammalian cells suggesting that certain of these proteins, or
perhaps complexes of these proteins, mediate signals in a ligand-
specific manner, in the process becoming phosphorylated and
translocated from cytoplasm to nucleus (Fig. 1)122—241.
Loss of TGF-p responsiveness may be common to a variety of
pathologies
There is now substantial evidence suggesting that the TGF-J3
receptors and downstream signaling pathway(s) constitute a tu-
mor suppressor pathway and that loss of either the receptors or
signaling intermediates is associated with carcinogenesis [15].
Specific examples include loss of TGF-13 type II receptors by a
mechanism called microsatellite instability [25] and involving
permutation of a polyadenine tract in the coding region of the
receptor in patients having genetic defects in DNA repair mech-
anisms [26], mutational inactivation of type II or type I receptor
kinase activity [27, 28], or by mutations resulting in a dominant
negative effect [291. The observation that microsatellite mutation
of the type II receptor is common in some but not in other cancers
characterized by replication error defects, demonstrates that
receptor loss is a selected trait in certain cancers, such as colon
and gastric carcinoma, in which it confers a growth advantage [30].
Preliminary studies in our laboratory also demonstrate that loss
of responsiveness to TGF-f3 in transgenic mice expressing a
dominant negative type II receptor predisposes to spontaneous
and experimentally-induced carcinogenesis, showing that it con-
tributes directly to tumor progression (E. BOttinger and L.
Wakefield, personal communication). Recently, two of the Mad
family proteins specifically implicated in signaling from TGF-13
ligands, Madr2 and dpc4 (also called Smad2 and Smad4), have
been shown to be candidate tumor suppressor genes in that they





Dysregulation of TGF-13 ligands in disease
Loss of TGF-f3 signaling is frequently associated with increased
expression of TGF-1. In carcinogenesis, this results in double
jeopardy. The tumor cell is no longer suppressed by autocrine
action of the TGF-/3 it secretes, allowing paracrine effects of the
secreted TGF-(3 to promote tumor growth indirectly by suppress-
ing immune surveillance, increasing desmoplasia, and enhancing
angiogenesis [14]. Moreover, as might have been predicted from
the strong effects of TGF-J3 on regulation of extracellular matrix
protein production, there is now an extensive body of literature
demonstrating overproduction of TGF-/31 in a host of fibrotic
diseases including glomerulonephritis, pulmonary fibrosis, and
liver cirrhosis [reviewed in 101. Blocking the TGF-/3 in experimen-
tal models of fibrosis ameliorates the symptoms, suggesting a
critical role for TGF-f3 in the disease process [35, 36]. On the
other hand, deficiency of TGF-/31 leads to defects in immune cells
as seen in experimental models of autoimmune disease [7, 8, 371.
Thus, in both allergic experimental encephalomyelitis, a model of
multiple sclerosis, and in experimental arthritis, injection of
TGF-pi suppresses symptoms of disease, whereas injection of
antibodies to TGF-pl exaggerate the process [7, 8]. This review
discusses the use of transgenic and knockout mouse models in
which TGF-f31 is either overexpressed or deficient, with an
emphasis on new insights that these models have provided into the
role of TGF-pl in clinical disease.
Fig. 1. TGF-s act through a tetrameric complex of two distinct receptor
types I and II, each of which has intrinsic serine-threonine kinase activity.
Ligand-activation of the receptor complex leads to phosphoiylation of the
type I receptor by the type II receptor kinase. Signal transduction is
mediated, at least in part, via cytoplasmic proteins belonging to the Mad
family. Data show that Smad3 (lighter shading) is associated with the
receptor complex [34] and that Smad4/DPC4 (darker shading) is also
necessary for signal transduction from TGF-p [34]. Smad2 [32] and Smad3
[34] are phosphorylated and translocated to the nucleus following treat-
ment of cells with TGF-f3. In the hypothetical scheme shown here, it is
proposed that different Smad proteins may form homodimeric or hetero-
meric complexes. The mechanisms whereby these proteins lead to gene
activation are currently unknown.
[3 1—33]; introduction of dpc4 into null tumor cells has been shown
to restore TGF-p signaling [34] (M. deCaestccker and R. Lechlci-
der, personal communication). Taken together, the data demon-
strate that TGF-p signals through a tumor suppressor pathway.
While escape from negative growth regulation by TGF-p now
appears to be common to many different cancers, this mechanism
has not been definitively implicated in other pathologies. How-
ever, preliminary studies in our laboratory suggest that a similar
mechanism may be involved in neurodegenerative diseases (K.
Flanders, personal communication).
Use of transgenic and knockout mouse models to study effects
of dysregulation of TGF-j31
TGF-f31 knockout mice: Implications of their phenotype
As noted above, TGF-f31 appears to be the predominant
isoform underlying numerous pathologies, including carcinogen-
esis, fibroproliferative, parasitic, and autoimmune diseases [6, 10].
With the development of gene targeting strategies, truly isoform-
specific activities are now gaining a more clear definition through
models in which the expression of each individual isoform has
been disrupted [38—41]. Indeed, while the phenotype of the
TGF-3-deficient mouse has defined this isoform as a critical
participant in the processes of palatogenesis and pulmonary
maturation during development, the initial evaluations of TGF-
f31-deficient mice have subtantiated the importance of this iso-
form in the maintenance of immunological homeostasis [38, 39,
42, 43]. In fact, these models clearly show that the isoforms are not
functionally redundant in vivo, and that selective loss of each
isoform yields a severe phenotype.
The predominant phenotype of the TGF-/31 knockout mouse
suggested the loss of a critical regulator of immune function. The
phenotype is best characterized as an excessive inflammatory
response, with a massive infiltration of leukocytes (principally
lymphocytes and macrophages) in several organs. Heart, lung,
liver, salivary gland, pancreas, stomach, and intestine are uni-
formly involved, with occasional involvement of brain, kidney, and
skeletal muscle. The syndrome develops rapidly, beginning during
the first week of life and resulting in severe wasting and death by
the fourth week of life [38, 39, 42].
The typical pattern of tissue infiltration in TGF-I-deficient
mice is perivascular in nature. It appears to evolve from the
earliest lesions, which are primarily defined by the increasing
adhesion of leukocytes to vascular endothelium, with ultimate
perivascular accumulation. The profound immune dysregulation
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that develops in the absence of TGF-pl gene expression is also
associated with an apparent alteration in the control of normal
hematopoiesis. The latter is a component of the phenotype that is
enhanced in backgrounds that obviate the evolution of the
inflammatory process [44], and may be linked to the loss of cell
cycle controls normally exerted by TGF-f31.
An emerging consensus regarding the predominant phenotype
is that it represents a unique and important model of autoimmu-
nity. In many other murine models of autoimmune disease,
including in the MRLIIpr model of systemic lupus erythematosis
(SLE) and murine experimental allergic encephalomyelitis (EAE)
[8, 45], endogenous production of TGF-j31 is seen as a natural
host reponse to the ongoing inflammatory process. Another
feature of the TGF-131 knockout mouse phenotype that is highly
suggestive of an autoimmunine basis for the phenotype is the
appearance of enhanced expression of antigens of the major
histocompatibility (MHC) class I and class II genes within several
peripheral tissues, first detected during the neonatal period [46].
Susceptibility to several autoimmune diseases has been linked to
MHC class II genes, as in insulin-dependent diabetes mellitus
(IDDM) and pemphigus vulgaris in humans, and in the NOD
mouse model of IDDM [47—49]. Moreover, our recent work now
documents the critical role of class II molecules in the pathogen-
esis of this phenotype, as it is absent in the CD4+ T cell-deficient,
MHC class II antigen-negative background [44].
Collectively, these data suggest that the absence of TGF-131, as
in the TGF-f31 null mice, might lead to an autoimmune process.
Other phenotypic features consistent with this interpretation are
the presence of SLE-like serum autoantibodies to nuclear anti-
gens, immune complex deposits in renal glomeruli, and a progres-
sive lymphocytic tissue infiltration similar to that present in
human autoimmune syndromes such as Sjogrens [37, 50]. These
model systems now provide a unique tool for the study of renal
pathologies typically associated with chronic immune disorders.
Overexpression of TGF-f31 under control of the albumin promoter
In the kidney, local production of TGF-/3 either by intrinsic
renal cells or by infiltrating inflammatory cells has been implicated
as a key mediator of tissue fibrosis [10]. In addition, up-regulation
of TGF-13 receptor expression as recently observed in experimen-
tal glomerulonephritis [51, 52] is in keeping with a model of
enhanced activity of the entire TGF-p signaling cascade in tissue
repair and remodeling.
There is now growing evidence that circulating TGF-131 may
have important effects in physiologic and pathophysiologic pro-
cesses. Expression of a TGF-131 transgene under the control of an
albumin promoter/enhancer (Alb/TGF-pl) in the liver of trans-
genic mice resulted not only in hepatic fibrosis, but was also
notable for myocarditis, atrophy of testis and pancreas, and renal
disease [53]. Renal lesions correlated well with increased levels of
circulating TGF-131 in different transgenic lines and were charac-
terized by progressive mesangial expansion, accumulation of
glomerular immune deposits and matrix proteins, and interstitial
fibrosis [54]. Glomerular deposits lacked complement and distrib-
uted predominantly in subendothelial and mesangial locations.
Renal failure with nephrotic syndrome was fatal in one quarter of
severely affected transgenic mice. These findings indicate that
chronically elevated circulating levels of TGF-31 induce progres-
sive glomerulosclerosis. Interestingly, local expression of TGF-131
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Fig. 2. TGF-pI is the only isoform of TGF-/3 involved in endocrine
trafficking. Action of TGF-f32 and TGF-133 is restricted to local autocrine
and paracrioe modes. The sources of endocrine TGF-131, the molecular
forms of the complexes, and the mode of targeting to cells and tissues are
presently unknown. Specific pathologies associated with increased levels
of TGF-pl in plasma suggest that the molecular "addresses" or chaper-
ones of TGF-31 secreted into the plasma from pathological sources such
as tumor cells may differ from those of physiological levels of the protein,
resulting in distinct targeting associated with the specific disease.
and TGF-J33 mRNAs in diseased transgenic kidneys did not differ
from nontransgenic control kidneys (M. Mozes, J. Kopp, personal
communication) pointing to a direct pathogenetic role for circu-
lating TGF-f31.
Physiological and pathological roles of endocrine trafficking of
TGF-/31
Evidence for a physiological role of circulating TGF-131 comes
from the unexpected discovery in TGF-f31(—/—) mice that
TGF-J31 is transferred from heterozygous mothers to their TGF-
131(—/—) progeny [55]. TGF-/31 was transferred both transpiacen-
tally and lactationally to fetuses and neonates, respectively, local-
izing in a tissue-specific manner to give an immunohistochemical
staining pattern in newborn TGF-f31(—/—) pups similar to that of
wild-type littermates. This transferred protein plays a critical role
in embryogenesis in that TGF-J31 null pups born to a TGF-pl null
mother uniformly displayed severe developmental defects in the
heart [55]. The particular carrier protein(s) involved in this
endocrine trafficking of TGF-/31 are not known, although a
relevant example may be the transfer of TGF-31 bound to IgG
that is taken up by macrophages via Fe receptors and delivered in
an active form to TGF-13 receptors on interacting lymphocytes [56,
57].
The presence of physiologically significant levels of TGF-pl in
plasma of normal human subjects suggests that endocrine traf-
ficking of TGF-/31 may play an important, yet undiscovered
physiological role [58]. Again, the physiological form of the
circulating TGF-f31 is unknown, although, based on the half-life of
only two to three minutes for active TGF-13, it is likely that the
TGF-131 is in the latent form or complexed to a molecule such as
thrombospondin [58]. While the source of plasma TGF-131 is not
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Fig. 3. TGF-p precursors are proteolytically
cleaved into the proregion (latency-associated
peptide or LAP) and mature TGF- LAP and
mature TGF- are noncovalently associated
and secreted as biologically inactive complexes.
"Small latent complexes" consist of LAP and
mature TGF-p. Latent TGF-/3 binding proteins
(LTBP5) may be covalently linked to small
latent complexes to form "large latent
complexes". Activation of latent TGF- leads
to release of active TGF- from latent
complexes. Proposed mechanisms of activation
include acidic pH, redox, thrombospondin,
mannose-6-P receptor, transglutaminase and
proteolytic cleavage by plasmin [reviewed in
661. Recombinant LAP can reassociate with
active TGF-p inactivating its biological activities
in vitro [681 and in vivo [691.
that it may be derived from bone marrow (J. Letterio, unpublished
observation). Importantly, this mode of trafficking is unique to the
type 1 isoform; plasma levels of TGF-J32 and TGF-/3-3 are
undetectable, suggesting that they are restricted to more localized
autocrine and paracrine modes of action (Fig. 2).
Several reports now suggest that endocrine trafficking of
TGF-/31 may not only be important in normal physiology, but also
that dysregulation of endocrine trafficking, as evidenced by either
excessive or deficient levels of TGF-131 in plasma, may predispose
to or be indicative of certain pathologies. As examples, elevated
plasma TGF-f31 has been shown to be the best marker of invasive
prostatic adenocarcinoma [59] and, in breast cancer patients, has
been found to be a strong positive predictor for lethal fibrotic
sequelae in liver and lung following bone marrow transplantation
[60]. Moreover, elevated serum levels of TGF-)31 are present in
thrombotic thrombocytopenic purpura [61]. As for physiological
levels of plasma TGF-pl, the molecular forms of excess TGF-pl
deposited into the plasma by cells such as tumor cells are
unknown [62]. However, the specific tissue targeting of this excess
circulating TGF-/31 suggests that it might have a unique chaper-
one resulting in a "molecular address" distinct from that of basal
levels.
In contrast, deficient levels of plasma TGF-pi show a strong
correlation to atherosclerosis. Patients with no vascular disease
had plasma levels of TGF-f31 in the normal range, whereas
patients having previously been diagnosed with significant steno-
ses of all three major coronory vessels all showed severe deficien-
cies in plasma TGF-131 levels [63]. Interesting in this regard is that
one of the genetic loci of hereditary hemorrhagic telangiectasia
has been shown to be endoglin [64], a molecule known to bind
TGF-131 and facilitate its interaction with its receptors on endo-
thelial cells [65]. Taken together, these two lines of evidence
suggest that either a deficiency of TGF-J31 or of its ability to signal
may impair physiological repair of blood vessel injury and predis-
pose to vessel disease. The recent backcross of the TGF-f31 null
mice into the nude background is now providing longer-lived mice
in which this aspect can be investigated (J. Letterio, unpublished
observations).
These observations in transgenic mouse models and in human
disease suggest that it will be important to define to what extent
circulating TGF-31 participates in the pathogenesis of chronic
fibrotic and proliferative diseases. In this context, understanding
of the physical form of circulating TGF-pl, its source and
regulation, as well as mechanisms of tissue sequestration will be
essential.
Latency-associated protein inhibits TGF-f31 activity in vitro
and in vivo
The three mammalian isoforms of TGF-13 (TGF-f31, TGF-j32
and TGF-p3) are secreted as latent complexes and activated
extracellularly with release of the active cytokines from their
noncovalently associated proregions, also known as latency-asso-
ciated peptides (LAP) (reviewed in [66]; Fig. 3). The proregion of
TGF-f31 (aa 30-278) [67], when independently expressed, associ-
ates noncovalently with active TGF-f3, inactivating its biological
activities in vitro [68]. We have examined whether systemic
administration of recombinant TGF-J31 LAP would decrease the
activity of excess active TGF-pl in vivo. The neutralizing activity
of recombinant LAP was assessed in a short-term assay measuring
hepatocyte proliferation in vivo in Alh/TGF-/31 transgenic mice
with elevated levels of bioactive TGF-/31 in the liver. Treatment
with LAP reversed suppression of the early proliferative response
induced by TGF-pI in remnant livers after partial hepatectomy,
indicating neutralization of the antiproliferative activity of ele-
vated TGF-131 during liver regeneration [69]. Studies of tissue
distribution of radioiodine-labeled LAP showed accumulation of
comparable levels of LAP in most parenchymal organs including
liver, lung and kidney. Of interest, our in vitro studies indicated
that TGF-J31 LAP inhibits active TGF-p2 and TGF-/33 with equal
potency when compared with active TGF-j31 [69]. Hence, TGF-/31
LAP may be a potent inhibitor of all three TGF-f3 isoforms. It will
be important to examine whether the promising TGF-/3 inhibitory
activity of LAP as demonstrated in the short-term liver regener-
ation assay can be sustained in more chronic disease models. In
this context, we are currently studying the effects of chronic
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administration of recombinant LAP on the development of
fibrotic kidney disease in Alb/TGF-f31 transgenic mice.
Future issues
New insights into the role of TGF-/3 in biology and pathobiol-
ogy have resulted from study of the TGF-/31 null and TGF-131
transgenic mice. Key observations such as striking autoimmunc
processes in TGF-/31 null mice or induction of fibrotic disease by
circulating TGF-1 in Alb/TGF-j31 transgenic mice have not been
predicted. Thus, a better understanding of the in vivo biology of
TGF-f3 is imperative to enable design of safe and effective
therapeutic strategies targeting the TGF-j3 system.
Reprint requests to Anita B. Roberts, Ph.D., Laboratoiy of Chemopreven-
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